BACKGROUND Agents with a high degree of selectivity for α1A receptors have beneficial effects on the symptoms associated with benign prostatic hyperplasia (BPH) and less effect on blood pressure. The α1 antagonists generally preferred in the management of BPH are Tamsulosin and Silodosin because of their minimal hemodynamic adverse effects. There have been only few comparative studies between these two drugs. Therefore, this study was undertaken to compare efficacy of silodosin and tamsulosin

more »

... treatment of lower urinary tract symptoms (LUTS) associated with BPH. MATERIALS AND METHODS A total of 70 newly diagnosed patients suffering from LUTS associated with BPH were randomly divided into two groups with 35 patients in each group. Tamsulosin group received Tamsulosin 0.4 mg orally once daily for 12 weeks and Silodosin group received Silodosin 8 mg orally once daily for 12 weeks. Assessment of efficacy was done by assessing improvement in the International Prostate Symptom Score (IPSS), Urinary Flow Rate (Qmax) and assessment of Quality of Life (QOL) at base line, 4 weeks and 12 weeks. RESULTS The changes in IPSS total score, Qmax and QOL were significant within the groups but not between the groups CONCLUSION Both the drugs are equally effective in treatment of LUTS associated with BPH. KEY WORDS Tamsulosin, Silodosin, LUTS, BPH, QOL. HOW TO CITE THIS ARTICLE: Yaraguppi AF, Ramesh H, Jadav R. A comparative study of efficacy and safety of tamsulosin and silodosin in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J. Evolution Med. Dent. Sci. 2019;8(02):146-151, DOI: 10.14260/jemds/2019/32 BACKGROUND Benign Prostatic Hyperplasia (BPH) is one of the most common diseases in men, with an increasing prevalence rate with age. 1 It clinically manifests as lower urinary tract symptoms (LUTS). BPH usually starts in men in their 50s, by the age of 60 years, 50% of men have histological evidence of BPH and 80% of men in their 70s suffer from BPH-related LUTS 2 . LUTS can be classified into three categories: voiding symptoms (Hesitancy, weak/slow stream, intermittency, straining, and incomplete voiding), storage symptoms (Frequency, urgency, nocturia, urge incontinence) and postmicturition symptoms (Postvoid dribbling), which may adversely affect the quality of life (QOL). 1 In addition, BPH can also lead to more serious complications such as acute urinary retention, recurrent urinary tract infections, hematuria, bladder calculi, and renal dysfunction. Histologically, BPH is